



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandra, Virginis 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/966,608	09/27/2001	Jonathan Braun	P-PM 4966	7273	
. 75	90 . 05/20/2003		•		
	& FLORES LLP	EXAMINER			
7th Floor 4370 La Jolla V	illage Drive		SCHEINER, LAURIE A		
San Diego, CA	92122		ART UNIT	PAPER NUMBER	
			1648	Н	
		•	DATE MAILED: 05/20/2003	·	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/966,608**

Applicant(s)

Braun et al.

Examiner

Laurie Scheiner

Art Unit 1648



	The MAILING DATE of this communication appears of	on th	cov	er she	et with	the c rrespondence address
Period 1	for Reply					
	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO E	XPIR	E	3	_ MONTH(S) FROM
	ions of time may be available under the provisions of 37 CFR 1.136 (a). In a	no even	t, how	ever, m	ay a reply	be timely filed after SIX (6) MONTHS from the
- If the p - If NO p - Failure - Any re	and date of this communication. Deriod for reply specified above is less than thirty (30) days, a reply within the Deriod for reply is specified above, the maximum statutory period will apply a to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nd will e e applic	expire ation 1	SIX (6) I	MONTHS 1 16 ABAND	from the mailing date of this communication. ONED (35 U.S.C. § 133).
Status						
1) 💢	Responsive to communication(s) filed on Jan 9, 200	03				
2a) 🗌	This action is FINAL . 2b) 💢 This action	ion is	non	-final.		
3) 🗆	Since this application is in condition for allowance e closed in accordance with the practice under <i>Ex pai</i>					
Disposi	tion of Claims					
4) 💢	Claim(s) 26, 28-42, and 45-57	<u> </u>				is/are pending in the application.
2	la) Of the above, claim(s)					is/are withdrawn from consideration.
5) 🗆	Claim(s)					is/are allowed.
6) 💢	Claim(s) 26, 28-42, and 45-57					is/are rejected.
7) 🗆	Claim(s)					is/are objected to.
8) 🗆	Claims			are	subjec	t to restriction and/or election requirement.
	ition Papers					
9) 🗆	The specification is objected to by the Examiner.					
10)	The drawing(s) filed on is/are	a) 🗌	ac	cepted	d or b)	Objected to by the Examiner.
	Applicant may not request that any objection to the d	rawin	g(s)	be hel	d in abe	eyance. See 37 CFR 1.85(a).
11)	The proposed drawing correction filed on			is:	a) 🗌 .	approved b) \square disapproved by the Examiner.
	If approved, corrected drawings are required in reply t	o this	Off	ice act	ion.	
12)	The oath or declaration is objected to by the Exami	ner.				
Priority	under 35 U.S.C. §§ 119 and 120					
13)	Acknowledgement is made of a claim for foreign pr	riority	und	ler 35	U.S.C	. § 119(a)-(d) or (f).
a)[☐ All b)☐ Some* c)☐ None of:					
	1. \square Certified copies of the priority documents hav	e bee	n re	ceive	d.	
	2. Certified copies of the priority documents have	e bée	n re	ceive	d in Ap	plication No
	3. Copies of the certified copies of the priority do application from the International Burea	au (Pi	CT F	lule 1	7.2(a)).	
	ee the attached detailed Office action for a list of the			•		
14)∐	Acknowledgement is made of a claim for domestic					
a) ∟	J. J					
15) L	Acknowledgement is made of a claim for domestic	priori	ty u	nder 3	35 U.S.	.C. 99 120 and/or 121.
Attachm	ent(s) stice of References Cited (PTO-892)	م ا ا	Inter	iou C.		O 412\ Paper No/a\
	ntice of Preferences Cited (P10-892) stice of Draftsperson's Patent Drawing Review (PT0-948)	_				O-413) Paper No(s) nt Application (PTO-152)
_	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6)			iiiai Falei	nt Application (F1 © 192)

Art Unit: 1648

Claims 26, 28-42 and 45-57 are pending. The finality of the rejection of the last Office action is withdrawn, as set forth by the Examiner Interview Summary Record of December 18, 2002.

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in a patent granted on an application for patent by another filed in the United States before the invention thereof by the applicant for patent, or on an international application by another who has fulfilled the requirements of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention thereof by the applicant for patent.

The changes made to 35 U.S.C. 102(e) by the American Inventors Protection Act of 1999 (AIPA) do not apply to the examination of this application as the application being examined was not (1) filed on or after November 29, 2000, or (2) voluntarily published under 35 U.S.C. 122(b). Therefore, this application is examined under 35 U.S.C. 102(e) prior to the amendment by the AIPA (pre-AIPA 35 U.S.C. 102(e)).

Claims 26, 28-31, 42, 45, 46 and 57 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Rubenfield et al. (US Patent No. 6,551,795 B1).

Rubenfield et al. clearly teach an isolated nucleic acid molecule comprising a portion of instant SEQ ID No:1, wherein the portion is 8 contiguous amino acids of instant SEQ ID No:2.

Please see the disclosure of **TCACTTCAAGAGCAAGGATGAG** SEQ ID No: 9721(nucleic acid) which corresponds to SEQ ID NO:26292 (amino acid) of the issued Patent.

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject

Art Unit: 1648

matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 26 and 28 are rejected under 35 U.S.C. 103(a) as being unpatentable over EMBL Online 1 November 1996 (1996-11-01) "Similar to a B. Subtilis Gene (GB: Bachemehy 50, " Accession number Q59306 (Meyer, J.) for applicable reasons of record.

Claims 32-41 and 47-56 are rejected under 35 U.S.C. 103(a) as being unpatentable over Rubenfield et al. (US Patent No. 6,551,795 B1).

Rubenfield et al. teach an isolated nucleic acid sequence encoding an amino acid sequence (SEQ ID No: 26292) having 100% identity with 25 consecutive amino acids of instant SEQ ID No:2. The degeneracy of the genetic code perfectly exemplifies the functional equivalency of all codons which encode the same single amino acid. Thus, in the absence of evidence to the contrary, all possible degenerate sequence variations resulting in expression product having the sequence: **GEAMAVLVYEWRSLSAEGQA** are obvious in view of the amino acid sequence set forth by SEQ ID No:26292.

Applicant's arguments with respect to claims 26, 28-42 and 45-56 have been considered but are most in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laurie Scheiner, whose telephone number is (703) 308-1122. Due to a flexible work schedule, the examiner's hours typically vary each day. However, the examiner can normally be reached Monday thru Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel, can be reached on (703) 308-4027.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group 1600 receptionist whose telephone number is (703) 308-0196.

Application/Control Number: 09/966,608

Art Unit: 1648

Page 4

Correspondence related to this application may be submitted to Group 1600 by facsimile transmission. The faxing of such papers must conform with the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). Official communications should be directed toward one of the following Group 1600 fax numbers: (703) 308-4242, (703) 305-3014, (703) 872-9306 or (703) 872-9307. Informal communications may be submitted directly to the Examiner through the following fax number: (703) 746-5226.

(10)

Laurie Scheiner/LAS May 19, 2003

> LAURIE SCHEINER PRIMARY EXAMINER